Pasithea Therapeutics Corp. (KTTA) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
| Previous Close | 0.5 |
| Open | 0.5 |
| Day High | 0.52 |
| Day Low | 0.5 |
| 52-Week High | 2.06 |
| 52-Week Low | 0.28 |
| Volume | 196,337 |
| Average Volume | 537,138 |
| Market Cap | 3.72M |
| PE | -0.35 |
| EPS | -1.41 |
| Moving Average 50 Days | 0.7 |
| Moving Average 200 Days | 0.81 |
| Change | -0 |
Pasithea Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
GlobeNewswire Inc.
Feb 17, 2026 12:01 PM GMT
– Virtual presentation scheduled for Thursday, February 26, 2026, at 4:00 PM ET –– Webcast may be accessed here – MIAMI, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the “Company”), a clinical-stage bi
Pasithea Therapeutics Provides Outlook on PAS-004 Clinical Programs and Data Release Timelines
GlobeNewswire Inc.
Jan 13, 2026 12:01 PM GMT
MIAMI, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation oral macrocyclic MEK inhibitor for the treatment of neur
Pasithea Therapeutics Announces Closing of $60 Million Public Offering of Common Stock
GlobeNewswire Inc.
Dec 02, 2025 12:00 PM GMT
Extends cash runway through at least the first half of 2028Led by healthcare-dedicated investors, including Vivo Capital, Janus Henderson Investors, Coastlands Capital, Columbia Threadneedle Investments, Adage Capital Partners and Squadron Capital Ma